Abstract
A cervical cytology biobank (CCB) is an extension of current cytopathology laboratory practice consisting in the systematic storage of Pap smears or liquid-based cytology samples from women participating in cervical cancer screening with the explicit purpose of facilitating future scientific research and quality audit of preventive services. A CCB should use an internationally agreed uniform cytology terminology, be integrated in a national or regional screening registry, and linked to other registries (histology, cancer, and vaccination). Legal and ethical principles concerning personal integrity and data safety must be respected strictly. Biobank-based studies require approval from ethical review boards.
A CCB constitutes a nearly inexhaustible resource to perform fundamental and applied biologic research. In particular, it can contribute in answering questions on the natural history of HPV infection and HPV-induced lesions and cancers, screening effectiveness, exploration of new biomarkers, and surveillance of short- and long-term effects of the introduction of HPV vaccination.
To understand the limitations of CCB, more studies are needed on quality of samples in relation to sample type, storage procedures, and duration of storage.
Key words
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Council of the European Union (2003) Council Recommendation of 2 December 2003 on Cancer Screening. Off. J. Eur. Union 878: 34–38.
Advisory Committee on Cancer Prevention (2000) Recommendations on cancer screening in the European Union. Advisory Committee on Cancer Prevention. Eur. J. Cancer 36: 1473–1478.
European Commission. European Guidelines for Quality Assurance in Cervical Cancer Screening – 2nd Edition. Arbyn M., Anttila A., Jordan J., Schenck U., Ronco G., Segnan N., and Wiener H., eds. (2008), 2nd edn. Office for Official Publications of the European Communities, Luxembourg.
Wiener H.G., Klinkhamer P., Schenck U., Arbyn M., Bulten J., Bergeron C., and Herbert A. (2007) European guidelines for quality assurance in cervical cancer screening: Recommendations for cytology laboratories. Cytopathology 18: 67–78.
Anttila A., Ronco G., Clifford G., Bray F., Hakama M., Arbyn M., and Weiderpass E. (2004) Cervical cancer screening programmes and policies in 18 European countries. Br. J. Cancer 91: 935–941.
Linos A. and Riza E. (2000) Comparisons of cervical cancer screening programmes in the European Union. Eur. J. Cancer 36: 2260–2265.
Ballegooijen M., van Marle M.E., Patnick J., Lynge E., Arbyn M., Anttila A., Ronco G., and Habbema D.F. (2000) Overview of important cervical cancer screening process values in EU-countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness. Eur. J. Cancer 36: 2177–2188.
Arbyn M. and Dillner J. (2007) Review of current knowledge on HPV vaccination: An appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. J. Clin. Virol. 38: 189–197.
Wallin K.L., Wiklund F., Angstrom T., Bergman F., Stendahl U., Wadell G., Hallmans G., and Dillner J. (1999) Type-specific persistence of human papillomavirus DNA before the development of invase cervical cancer. N. Engl. J. Med. 341: 1633–1638.
Ylitalo N., Sorensen P., Josefsson A.M., Magnusson P.K.E., Andersen P.K., Ponten J., Adami H.-O., Gyllensten U.B., and Melbye M. (2000) Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: A nested case-control study. Lancet 355: 2194–2198.
Ylitalo N., Josefsson A., Melbye M., Sorensen P., Frisch M., Andersen P.K., Sparen P., Gustafsson M., Magnusson P., Ponten J., Gyllensten U., and Adami H.O. (2000) A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ. Cancer Res. 60: 6027–6032.
Zielinski G.D., Snijders P.J., Rozendaal L., Voorhorst F.J., van der Linden H.C., Runsink A.P., De Schipper F.A., and Meijer C.J.L.M. (2001) HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears. Br. J. Cancer 85: 398–404.
Hamidi A.E., Liu H., Zhang Y., Hamoudi R., Kocjan G., and Du M.Q. (2002) Archival cervical smears: A versatile resource for molecular investigations. Cytopathology 13: 291–299.
van der Graaf Y., Molijn A., Doornewaard H., Quint W., van Doorn L.J., and van den Tweel J. (2002) Human papillomavirus and the long-term risk of cervical neoplasia. Am. J. Epidemiol. 156: 158–164.
Gunnell A.S., Tran T.N., Torrang A., Dickman P.W., Sparen P., Palmgren J., and Ylitalo N. (2006) Synergy between cigarette smoking and human papillomavirus type 16 in cervical cancer in situ development. Cancer Epidemiol. Biomarkers Prev. 15: 2141–2147.
Burghardt E. (1970) Latest aspects of precancerous lesions in squamous and columnar epithelium of the cervix. Int. J. Gynecol. Obstet. 8: 573–580.
Burghardt E., Pickel H., and Girardi F. Colposcopy Cervical Pathology. eds. (1998), 3rd revised and enlarged edition. Georg Thieme Verlag, Stuttgart.
Boon M.E. and Suurmeijer A.J.H. The Pap Smear. eds. (1993), 2nd edition. Coulomb Press Leyden.
Arbyn M., Herbert A., Schenck U., Nieminen P., Jordan J., McGoogan E., Patnick J., Bergeron C., Baldauf J.J., Klinkhamer P., Bulten J., and Martin-Hirsch P. (2007) European guidelines for quality assurance in cervical cancer screening: Recommendations for collecting samples for conventional and liquid-based cytology. Cytopathology 18: 133–139.
BSCC. How to take a cervical smear (3rd edition). 2003. Uxbridge, British Society of Clinical Cytology
NCCLS (1994) Papanicolaou technique; approved guideline. National Comity for Clinical Laboratory Standards, Pensylvania.
Koss L. and Gompel C. Introduction to gynecologic cytopathology with histologic and clinical correlations. Mitchell C.W., eds. (1999), Pradel edn.
Howell L.P., Davis R.L., Belk T.I., Agdigos R., and Lowe J. (1998) The AutoCyte preparation system for gynecologic cytology. Acta Cytol. 42: 171–177.
Hutchinson M.L., Isenstein L.M., Goodman A., Hurley A., Douglas K.L., Mui K.K., Patten F.W., and Zahniser D.J. (1994) Homogeneous sampling accounts for the increased diagnostic accuracy using the thinprep processor. Am. J. Clin. Pathol. 101: 215–219.
Austin R.M. and Ramzy I. (1998) Increased detection of epithelial cell abnormalities by liquid-based gynecologic cytology preparations. Acta Cytol. 42: 178–184.
Linder J. and Zahniser D. (1997) The ThinPrep Pap test. A review of clinical studies. Acta Cytol. 41: 30–38.
Ferenczy A. and Franco E.L. (1997) Human Papillomavirus DNA testing using liquid-based cytology, in: New Developments in Cervical Cancer Screening and Prevention (Franco, E. L. and Monsonego, J., eds.), Blackwell Science, Cambridge, pp. 343–353.
Sherman M.E., Schiffman M.H., Lorincz A.T., Herrero R., Hutchinson M.L., Bratti C., Zahniser D., Morales J., Hildesheim A., Helgesen K., Kelly D., Alfaro M., Mena F., Balmaceda I., Mango L., and Greenberg M. (1997) Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing. Cancer 81: 89–97.
Solomon D., Davey D., Kurman R., Moriarty A., O’Connor D., Prey M., Raab S., Sherman M.E., Wilbur D., Wright T.C., and Young N. (2002) The 2001 Bethesda System: Terminology for reporting results of cervical cytology. JAMA 287: 2114–2119.
Herbert A., Bergeron C., Wiener H., Schenck U., Klinkhamer P.J., Bulten J., and Arbyn M. (2007) European guidelines for quality assurance in cervical cancer screening: Recommendations for cervical cytology terminology. Cytopathology 18: 213–219.
Castle P.E., Solomon D., Hildesheim A., Herrero R., Concepcion B.M., Sherman M.E., Rodriguez A.C., Alfaro M., Hutchinson M.L., Terence D.S., Kuypers J., and Schiffman M.A. (2003) Stability of archived liquid-based cervical cytologic specimens. Cancer 99: 89–96.
Bergeron C., Cas F., Fagnani F., Didailler-Lambert F., and Poveda J.D. (2006) Human papillomavirus testing with a liquid-based system: Feasibility and comparison with reference diagnoses. Acta Cytol. 50: 16–22.
Canfell K., Gray W., Snijders P.J., Murray C., Tipper S., Drinkwater K., and Beral V. (2004) Factors predicting successful DNA recovery from archival cervical smear samples. Cytopathology 15: 276–282.
Moberg M., Gustavsson I., and Gyllensten U. (2004) Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int. J. Cancer 112: 854–859.
Tarkowski T.A., Rajeevan M.S., Lee D.R., and Unger E.R. (2001) Improved detection of viral RNA isolated from liquid-based cytology samples. Mol. Diagn. 6: 125–130.
Cuschieri K.S., Beattie G., Hassan S., Robertson K., and Cubie H. (2005) Assessment of human papillomavirus mRNA detection over time in cervical specimens collected in liquid based cytology medium. J. Virol. Methods 124: 211–215.
Powell N., Smith K., and Fiander A. (2006) Recovery of human papillomavirus nucleic acids from liquid-based cytology media. J. Virol. Methods 137: 58–62.
Boulet G.A.V., Horvath C.A.J., Berghmans S., Moeneclaey L.M., Duys I.S.M., Arbyn M., Depuydt C.E., Vereecken A.J., Sahebali S., and Bogers J.J. (2008) Cervical cytology biobanking: Quality of DNA from archival cervical Pap-stained smears. J. Clin. Pathol. 61(5), 637–641.
Depuydt C., Vereecken A.J., Salembier G.M., Vanbrabant A.S., Boels L.A., van Herck E., Arbyn M., Segers K., and Bogers J.J. (2003) Thin-layer liquid-based cervical cytology and PCR for detecting and typing human papillomavirus DNA in Flemish women. Br. J. Cancer 88: 560–566.
Horvath C.A., Boulet G., Sahebali S., Depuydt C., Vermeulen T., Vanden Broeck D., Vereecken A., and Bogers J. (2007) Effects of fixation on RNA integrity in a liquid-based cytology setting. J. Clin. Pathol.
Cuschieri K.S., Whitley M.J., and Cubie H.A. (2004) Human papillomavirus type specific DNA and RNA persistence – Implications for cervical disease progression and monitoring. J. Med. Virol. 73: 65–70.
Molden T., Nygard J.F., Kraus I., Karlsen F., Nygard M., Skare G.B., Skomedal H., Thoresen S.O., and Hagmar B. (2005) Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL pap smear. Int. J. Cancer 114: 973–976.
Chuaqui R., Cole K., Cuello M., Silva M., Quintana M.E., and Emmert-Buck M.R. (1999) Analysis of mRNA quality in freshly prepared and archival Papanicolaou samples. Acta Cytol. 43: 831–836.
Liu H., Huang X., Zhang Y., Ye H., El Hamidi A., Kocjan G., Dogan A., Isaacson P.G., and Du M.Q. (2002) Archival fixed histologic and cytologic specimens including stained and unstained materials are amenable to RT-PCR. Diagn. Mol. Pathol. 11: 222–227.
Iftner T. and Villa L.L. (2003) Chapter 12: Human papillomavirus technologies. J. Natl. Cancer Inst. Monogr. 80–88.
Arbyn M., Sasieni P., Meijer C.J., Clavel C., Koliopoulos G., and Dillner J. (2006) Chapter 9: Clinical applications of HPV testing: A summary of meta-analyses. Vaccine 24 S3: 78–89.
Cuzick J., Mayrand M.H., Ronco G., Snijders P., and Wardle J. (2006) Chapter 10: New dimensions in cervical cancer screening. Vaccine 24: 90–97.
Arbyn M., Dillner J., Schenck U., Nieminen P., Weiderpass E., Da Silva D. et al. (2007) Chapter 3: Methods for screening and diagnosis, in: European Guidelines for Quality Assurance in Cervical Cancer Screening (Arbyn, M., Anttila, A., Jordan, J., Ronco, G., Schenck, U., Segnan, N., Wiener, H. and European Commission, eds.), Office for Official Publications of the European Communities, Luxembourg, pp. 1–69.
Coutlee F., Gravitt P., Kornegay J., Hankins C., Richardson H., Lapointe N., Voyer H., and Franco E. (2002) Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples. J. Clin. Microbiol. 40: 902–907.
de Roda Husman A.M., Walboomers J.M., van den Brule A.J., Meijer C.J.L.M., and Snijders P.J. (1995) The use of general primers GP5 and GP6 elongated at their 3’ end with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J. Gen. Virol. 76: 1057–1062.
Söderlund-Strand A., Carlson J., and Dillner J. (2009) Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomaviruses. J. Clin. Microbiol. 47: 541–546.
Kleter B., van Doorn L.J., Schrauwen L., van Krimpen K., Burger M., ter Harmsel B., and Quint W. (1998) Novel short-fragment PCR assey for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am. J. Pathol. 153: 1731–1739.
Kleter B., van Doorn L.J., Schrauwen L., Molijn A., Sastrowijoto S., ter Schegget J., Lindeman J., ter Harmsel B., Burger M., and Quint W. (1999) Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J. Clin. Microbiol. 37: 2508–2517.
Söderlund-Strand A., Dillner J., and Carlson J. (2008) High-throughput genotyping of oncogenic human papillomaviruses with MALDI-TOF mass spectrometry. Clin. Chem. 54: 86–92.
Sotlar K., Selinka H.C., Menton M., Kandolf R., and Bultmann B. (1998) Detection of human papillomavirus type 16 E6/E7 oncogene transcripts in dysplastic and nondysplastic cervical scrapes by nested RT-PCR. Gynecol. Oncol. 69: 114–121.
Smits H.L., van Gemen B., Schukkink R., Van der Velden J., Tjong A.H., Jebbink M.F., and ter Schegget J. (1995) Application of the NASBA nucleic acid amplification method for the detection of human papillomavirus type 16 E6-E7 transcripts. J. Virol. Methods 54: 75–81.
Martin C.M., Astbury K., and O’Leary J.J. (2006) Molecular profiling of cervical neoplasia. Expert. Rev. Mol. Diagn. 6: 217–229.
Keating J.T., Ince T., and Crum C.P. (2001) Surrogate biomarkers of HPV infection in cervical neoplasia screening and diagnosis. Adv. Anat. Pathol. 8: 83–92.
zur Hausen H. (2002) Papillomaviruses and cancer: From basic studies to clinical application. Nat. Rev. Cancer 2: 342–350.
IARC. Cervix Cancer Screening. IARC Handbooks of Cancer Prevention. Vol. 10. eds. (2005). IARCPress, Lyon.
von Knebel D.M. (2002) New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur. J. Cancer 38: 2229–2242.
Sahebali S., Depuydt C., Boulet G.A., Arbyn M., Moeneclaey L.M., Vereecken A.J., van Marck E.A., and Bogers J.J. (2006) Immunocytochemistry in liquid-based cervical cytology: Analysis of clinical use following a cross-sectional study. Int. J. Cancer 118: 1254–1260.
Wentzensen N., Bergeron C., Cas F., Eschenbach D., Vinokurova S., and von Knebel D.M. (2005) Evaluation of a nuclear score for p16(INK4a)-stained cervical squamous cells in liquid-based cytology samples. Cancer 461–467.
Bergeron C., Wentzensen N., Cas F., and Doeberitz M.V. (2006) The p16INK4a protein: A cytological marker for detecting high grade intraepithelial neoplasia of the uterine cervix. Ann. Pathol. 26: 397–402.
Klaes R., Friedrich T., Spitkovsky D., Ridder R., Rudy W., Petry U., Dallenbach-Hellweg G., Schmidt D., and von Knebel D.M. (2001) Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int. J. Cancer 92: 276–284.
Nieh S., Chen S.-F., Chu T.-Y., Lai H.-C., and Fu E. (2003) Expression of p16INK4A in Papanicolaou smears containing atypical squamous cells of undetermined significance from the uterine cervix. Gynecol. Oncol. 91: 201–208.
Wulfkuhle J.D., Liotta L.A., and Petricoin E.F. (2003) Proteomic applications for the early detection of cancer. Nat. Rev. Cancer 3: 267–275.
Kuramitsu Y. and Nakamura K. (2006) Proteomic analysis of cancer tissues: Shedding light on carcinogenesis and possible biomarkers. Proteomics 6: 5650–5661.
Yim E.K. and Park J.S. (2006) Role of proteomics in translational research in cervical cancer. Expert. Rev. Proteomics. 3: 21–36.
Ozols R.F., Herbst R.S., Colson Y.L., Gralow J., Bonner J., Curran W.J., Jr., Eisenberg B.L., Ganz P.A., Kramer B.S., Kris M.G., Markman M., Mayer R.J., Raghavan D., Reaman G.H., Sawaya R., Schilsky R.L., Schuchter L.M., Sweetenham J.W., Vahdat L.T., and Winn R.J. (2007) Clinical cancer advances 2006: Major research advances in cancer treatment, prevention, and screening – A report from the American Society of Clinical Oncology. J. Clin. Oncol. 25: 146–162.
Sasieni P., Adams J., and Cuzick J. (2003) Benefit of cervical screening at different ages: Evidence from the UK audit of screening histories. Br. J. Cancer 89: 88–93.
Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., Snijders P.J., and Meijer C.J. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348: 518–527.
Lehtinen M., Dillner J., Knekt P., Luostarinen T., Aromaa A., Kirnbauer R., Koskela P., Paavonen J., Peto R., Schiller J.T., and Hakama M. (1996) Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: Nested case-control study. BMJ 312: 537–539.
Dillner J., Lehtinen M., Bjorge T., Luostarinen T., Youngman L., Jellum E., Koskela P., Gislefoss R.E., Hallmans G., Paavonen J., Sapp M., Schiller J.T., Hakulinen T., Thoresen S., and Hakama M. (1997) Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. J. Natl. Cancer Inst. 89: 1293–1299.
Laukkanen P., Koskela P., Pukkala E., Dillner J., Laara E., Knekt P., and Lehtinen M. (2003) Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J. Gen. Virol. 84: 2105–2109.
Bray F., Loos A.H., McCarron P., Weiderpass E., Arbyn M., Moller H., Hakama M., and Parkin D.M. (2005) Trends in cervical squamous cell carcinoma incidence in 13 European countries: Changing risk and the effects of screening. Cancer Epidemiol. Biomarkers Prev. 14: 677–686.
Arbyn M., Raifu A.O., Autier P., and Ferlay J. (2007) Burden of cervical cancer in Europe: Estimates for 2004. Ann. Oncol. 18: 1708–1715.
Cheung A.N. (2007) Molecular targets in gynaecological cancers. Pathology 39: 26–45.
Dillner J., Arbyn M., and Dillner L. (2007) Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination. Clin. Exp. Immunol. 148: 199–207.
Lehtinen M., Kaasila M., Pasanen K., Patama T., Palmroth J., Laukkanen P., Pukkala E., and Koskela P. (2006) Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s. Int. J. Cancer 119: 2612–2619.
Lehtinen M., Herrero R., Mayaud P., Barnabas R., Dillner J., Paavonen J., and Smith P.G. (2006) Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. Vaccine 24: 233–241.
Hansson M.G., Dillner J., Bartram C.R., Carlson J.A., and Helgesson G. (2006) Should donors be allowed to give broad consent to future biobank research? Lancet Oncol. 7: 266–269.
Hansson M.G. (2005) Building on relationships of trust in biobank research. J. Med. Ethics 31: 415–418.
Helgesson G., Dillner J., Carlsson J., Bartram C.R., and Hansson M.G. (2007) Ethical framework for previously collected biobank samples. Nat. Biotechnol. 25: 973–975.
Arbyn M., Wallyn S., Van Oyen H., Nys H., Dhont J., and Seutin B. (1999) The new privacy law in Belgium: A legal basis for organised cancer screening. Eur. J. Health Law 6: 401–407.
Acknowledgments
We thank Prof. M.G. Hansson (Centre for Bioethics at Karolinska Institutet and Uppsala University, Uppsala Science Park, SE-75185 Uppsala, Sweden) and Don Chalmers (Faculty of Law School, University of Tasmania, Australia) for the review of subchapter 9 on legal and ethical issues. We are also grateful to Cindy Simoens (Scientific Institute of Public Health, Brussels) for editorial assistance.
Funding was received from the 6th Framework Programme (European Commission, DG Research, Brussels, Belgium) through the CCPRB Network (University of Lund, Malmö, Sweden), the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT-Vlaanderen, refnum 060081), and the Belgian Cancer Foundation.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Arbyn, M., Andersson, K., Bergeron, C., Bogers, JP., von Knebel-Doebertitz, M., Dillner, J. (2011). Cervical Cytology Biobanks as a Resource for Molecular Epidemiology. In: Dillner, J. (eds) Methods in Biobanking. Methods in Molecular Biology, vol 675. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59745-423-0_15
Download citation
DOI: https://doi.org/10.1007/978-1-59745-423-0_15
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-58829-995-6
Online ISBN: 978-1-59745-423-0
eBook Packages: Springer Protocols